Most CML patients have major bcr-abl (M-bcr) transcripts but a small minority possessing exclusively a minor bcr-abl (m-bcr) transcript has been described.
/l. BM examination at that time revealed that 99.0% of cells were peroxidase-negative leukemic blasts. These cells were positive for CD10, CD19, CD20, CD34, and HLA-DR. Chromosome analysis revealed Philadelphia chromosome (Ph) positivity in 14/ 20 analyzed metaphase cells. However, M-bcr transcripts were not present (by RT-PCR), but m-bcr were. From these findings, the patient was initially diagnosed as Ph-positive ALL (FAB L2).
Remission induction chemotherapy for ALL consisting of cyclophosphamide (CY), vincristine, daunorubicin, L-asparaginase and prednisolone was started in September 2000. After therapy, the patient achieved CR with a 0.8% blast count in BM. Chromosome analysis indicated normal karyotype (46, XX in 20/20 metaphase cells) and FISH analysis for bcr-abl transcripts was within the normal range ( Figure 1 ). The patient received high-dose ara-C treatment as consolidation chemotherapy. After therapy, in December 2000, the patient maintained CR with a normal blood cell count but the number of BM cells carrying bcr-abl transcripts by FISH analysis increased to 6.8%. In January 2001, after the second consolidation chemotherapy, this value was markedly increased to 70.8%. The patient was diagnosed as having had m-bcr þ CML in lymphoid BC at presentation and was referred to our hospital for CBT in After conditioning, consisting of TBI 2 Gy twice daily on days À6 to À4 (total 12 Gy) and CY 60 mg/kg once daily i.v. on days À3 and À2 (total dose 120 mg/kg), 2.28 Â 10 /l was seen on day þ 30. The patient developed maculo-papular rash on day þ 18, which was diagnosed as acute GVHD grade I skin þ þ , and confirmed by skin biopsy. Steroid treatment led to rapid resolution of the skin eruptions. BM examination on day þ 28 revealed no leukemic blasts and normal cytogenetics. Genetic testing for variable numbers of tandem repeats confirmed donor-type engraftment. BMA on day þ 56 revealed CR, and FISH for bcr-abl was negative. However, 62.2 copies/mg RNA of minor bcr-abl transcripts was detected on day þ 56, these could no longer be detected thereafter. The patient has not developed chronic GVHD. She is alive and in molecular remission 43 years post-CBT.
A review of the 23 previously described cases of m-bcr þ CML by Hur et al. 5 showed that monocytosis, absence of basophilia, and splenomegaly are found in 55.0, 55.0, and 70.0% of patients, respectively. In cases with monocytosis, it is important to differentiate them from chronic myelomonocytic leukemia. 6 Among these 23 reported cases, only three presented with an onset of BC: in all three cases lymphoid. [7] [8] [9] These cases, now totaling four including the present one, strongly suggest that lymphoid differentiation is induced by m-bcr during crisis. ALL-type induction chemotherapy was performed for all these four cases and although hematological remission was consistently achieved, m-bcr fusion transcripts persisted during remission.
In this case, because the patient was initially diagnosed as having Ph-positive ALL, ALL-type induction chemotherapy was performed and CR with normal karyotype was achieved. However, although CR was maintained in the BM, FISH analysis identified up to 90% bcr-abl þ cells during consolidation chemotherapy. Despite this, monocytosis was not observed and the NAP score was low during CR.
There have been few reports of allo-SCT for m-bcr þ CML thus far. Here, we present the first case of CBT for m-bcr þ CML. In this patient, although RT-PCR for m-bcr transcripts was still positive 2 months post-CBT, indicating the presence of MRD; it became negative thereafter. The patient remained in molecular remission after CBT without the administration of imatinib. These findings strongly suggest the existence of a GVL effect mediated by CBT also in patients with m-bcr þ CML. Although there are no clinical data on imatinib treatment in m-bcr þ CML, should resistant disease emerge, allo-SCT including CBT should be considered for these patients. RT-PCR analysis for minor bcr-abl transcripts (d). Quantitative levels of minor bcr-abl transcripts. Ind ¼ induction therapy; Con ¼ consolidation therapy; ND ¼ not done.
